Molecular diagnostics firm Biodesix has introduced GeneStrat, a targeted liquid biopsy mutation test for genotyping tumors of patients with advanced non-small cell lung cancer (NSCLC).
The blood test will provide results within 72 hours, offering physicians actionable diagnostic information that helps to take treatment decisions.
Biodesix CEO David Brunel said: "GeneStrat provides the tumor mutation profile at the time of diagnosis and can be used to monitor resistance by tracking the rise of the EGFR T790M mutation.
"For a more complete picture of the patient’s disease, GeneStrat can also be paired with VeriStrat, which captures the host response to the tumor – prognostic information early in treatment planning and predictive information for patients who are ineligible for platinum doublet chemotherapy or after progression on first line treatment."
GeneStrat is said to specifically focus on the clinically actionable EGFR, KRAS, and BRAF mutations that are frequently used to guide targeted therapy treatment decisions.
It also captures the EGFR T790M mutation that can be used to monitor the emergence of the primary resistance mutation in the EGFR gene.
According to the company, GeneStrat uses the ddPCR platform to analyze cell-free tumor DNA and is highly concordant with tissue analysis.